Tosaki A, Pali T, Droy-Lefaix M T
University of Connecticut Health Center, Farmington, USA.
Diabetologia. 1996 Nov;39(11):1255-62. doi: 10.1007/s001250050567.
Effects of preconditioning and Ginkgo biloba extract (EGb 761) were studied in isolated nondiabetic and diabetic ischaemic and re-perfused rat hearts. Hearts were randomly divided into five groups in both the age-matched non-diabetic and the 8-week streptozotocin-induced diabetic groups: Group I, hearts were subjected to 30 min of global ischaemia followed by 30 min of re-perfusion; Group II, one cycle of preconditioning consisting of 5 min ischaemia and 10 min re-perfusion before the induction of 30 min of ischaemia and 30 min of re-perfusion; Group III, two cycles of preconditioning; Group IV, three cycles; and Group V, four cycles before the onset of 30 min ischaemia followed by 30 min of re-perfusion. Four cycles of ischaemic preconditioning resulted in a reduction of arrhythmias in non-diabetic rats. Thus, in non-diabetics, the incidence of ventricular fibrillation and tachycardia fell from 92% and 100% (no preconditioning) to 33% (p < 0.05) and 42% (p < 0.05), respectively. Four cycles of preconditioning failed to reduce the incidence of re-perfusion arrhythmias in diabetic subjects. Preconditioning reduced the formation of oxygen free radicals measured by electron spin resonance spectroscopy, but the recovery of cardiac function was low in all non-diabetic and diabetic preconditioned groups. EGb 761 at 25 and 50 mg/kg improved cardiac function in non-preconditioned and preconditioned non-diabetic and diabetic hearts. During re-perfusion in the four-cycle preconditioned non-diabetic and diabetic groups, the amount of free radicals was reduced approximately by 50 and 70% using 25 and 50 mg/kg of EGb 761, respectively. EGb 761 improved cardiac function after ischaemia in both non-preconditioned and preconditioned non-diabetic and diabetic rats. Our data suggest that diabetes could abolish the precondition-induced protection.
在离体的非糖尿病和糖尿病缺血再灌注大鼠心脏中研究了预处理和银杏叶提取物(EGb 761)的作用。在年龄匹配的非糖尿病组和8周链脲佐菌素诱导的糖尿病组中,心脏均被随机分为五组:第一组,心脏接受30分钟全心缺血,随后30分钟再灌注;第二组,在诱导30分钟缺血和30分钟再灌注之前进行一个由5分钟缺血和10分钟再灌注组成的预处理周期;第三组,两个预处理周期;第四组,三个预处理周期;第五组,在30分钟缺血开始前进行四个预处理周期,随后30分钟再灌注。四个缺血预处理周期可减少非糖尿病大鼠的心律失常。因此,在非糖尿病大鼠中,室颤和心动过速的发生率分别从92%和100%(未预处理)降至33%(p<0.05)和42%(p<0.05)。四个预处理周期未能降低糖尿病受试者再灌注心律失常的发生率。预处理可减少通过电子自旋共振光谱法测量的氧自由基形成,但在所有非糖尿病和糖尿病预处理组中,心脏功能的恢复均较低。25和50mg/kg的EGb 761可改善未预处理和预处理的非糖尿病及糖尿病心脏的心脏功能。在四个周期预处理的非糖尿病和糖尿病组再灌注期间,使用25和50mg/kg的EGb 761时,自由基量分别减少约50%和70%。EGb 761可改善未预处理和预处理的非糖尿病及糖尿病大鼠缺血后的心脏功能。我们的数据表明,糖尿病可能会消除预处理诱导的保护作用。